{
    "nctId": "NCT01091428",
    "briefTitle": "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",
    "officialTitle": "Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 191,
    "primaryOutcomeMeasure": "Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel",
    "eligibilityCriteria": "Inclusion Criteria:\n\nEach participant must meet all of the following inclusion criteria to be enrolled in the study:\n\n* Female participants 18 years or older\n* Previously treated, metastatic or locally recurrent malignancy with 1 of the following diagnoses, which has been confirmed histologically or cytologically: adenocarcinoma of the breast (Phase 1 only), recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Phase 1 and 2)\n* In the Phase 1 portion of the study, participants with breast cancer must have received treatment with at least 1 but no more than 4 prior chemotherapy regimens not including regimens received in the neoadjuvant and/or adjuvant setting\n* Participants with breast cancer must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* No antineoplastic therapy or radiotherapy within 3 weeks before enrollment (2 weeks for regimens with recovery expected within 7 to 14 days) and recovered from toxicities of prior therapy (except alopecia); the participant must have recovered from all treatment-related toxicities and must have evidence of progressive disease (PD) or persistent disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate bone marrow, liver and renal function\n* Postmenopausal at least 1 year, OR Surgically sterile, OR If childbearing potential, agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse\n* Able to provide written informed consent\n* Willing to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures\n* Suitable venous access\n\nSpecific Inclusion Criteria for participants with Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer:\n\n* Prior treatments must have included a platinum and a taxane; the most recent treatment need not be a platinum-containing or taxane-containing regimen\n* Disease must have recurred \u2264 12 months after discontinuation of platinum therapy\n* Participants who previously received weekly taxane are potentially eligible, provided that they did not progress during therapy or within 3 months of completing therapy\n* Participants with platinum-refractory disease, as defined by progression during primary or subsequent platinum-based therapy or persistent radiographic disease after primary or subsequent platinum-based therapy, will be included\n* Participants must have measurable disease in target lesions or assessable disease (defined by cancer antigen-125 - CA-125 per protocol), and disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or modified Gynecologic Cancer Intergroup (GCIG) CA-125 criteria\n\nExclusion Criteria:\n\nParticipants meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n* Prior treatment with an Aurora A-targeted agent (including MLN8237)\n* Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study\n* Treatment with more than 4 cytotoxic chemotherapy regimens in the metastatic setting; prior therapy cannot include more than 2 prior taxane-containing regimen. Current use of tamoxifen, thalidomide, or any agent used as maintenance or consolidation therapy for OC.\n* Known hypersensitivity to Cremophor\u00ae EL, paclitaxel or its components\n* Prior history of \u2265 Grade 2 neurotoxicity or any toxicity requiring discontinuation from taxane chemotherapy that is not resolved to \u2264 Grade 1\n* Comorbid or unresolved toxicity that would preclude administration of weekly paclitaxel\n* Primary central nervous system malignancy or carcinomatous meningitis\n* Symptomatic brain metastasis\n* Inability to swallow oral medications or maintain a fast\n* History of hemorrhagic or thrombotic cerebrovascular event in past 12 months\n* Surgery within 3 weeks before study enrollment and not fully recovered\n* Diagnosis or treatment of another malignancy within 2 years preceding first dose of MLN8237 and have any evidence of residual disease except nonmelanoma skin cancer or in situ malignancy completely resected\n* Pregnant or lactating\n* Serious illness that could interfere with protocol completion\n* Investigational treatment 21 days prior to first dose of MLN8237\n* Prior allogeneic bone marrow or organ transplantation\n* Infection requiring systemic antibiotic therapy within 14 days prior to first dose of MLN8237\n* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C\n* Radiotherapy to \\> 25% bone marrow or whole pelvic radiotherapy\n* Requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes. Intermittent uses of antacids of H2 antagonists are allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}